Merck & Co., Inc. (NYSE: MRK) has recently received a number of price target changes and ratings updates:
- 11/7/2026 – Merck & Co., Inc. was upgraded by Wall Street Zen from “hold” to “strong-buy”.
- 11/3/2026 – Merck & Co., Inc. is now covered by Argus. They set a “strong-buy” rating on the stock.
- 11/3/2026 – Merck & Co., Inc. was downgraded by DZ Bank from “buy” to “hold”. They now have a $153.00 price target on the stock.
- 11/2/2026 – Merck & Co., Inc. had its price target raised by Freedom Broker from $125.00 to $140.00. They now have a “hold” rating on the stock.
- 11/2/2026 – Merck & Co., Inc. had its price target raised by Cantor Fitzgerald from $145.00 to $155.00. They now have a “neutral” rating on the stock.
- 10/30/2026 – Merck & Co., Inc. had its price target raised by JPMorgan Chase & Co. from $165.00 to $175.00. They now have an “overweight” rating on the stock.
- 10/30/2026 – Merck & Co., Inc. had its price target lowered by Royal Bank Of Canada from $145.00 to $140.00. They now have a “sector perform” rating on the stock.
- 10/30/2026 – Merck & Co., Inc. had its price target raised by Guggenheim from $170.00 to $171.00. They now have a “buy” rating on the stock.
- 10/26/2026 – Merck & Co., Inc. had its price target raised by Barclays from $150.00 to $180.00. They now have an “overweight” rating on the stock.
- 10/19/2026 – Merck & Co., Inc. was downgraded by Zacks Research from “hold” to “strong sell”.
- 10/12/2026 – Merck & Co., Inc. had its price target raised by Citigroup from $125.00 to $145.00. They now have a “neutral” rating on the stock.
- 10/12/2026 – Merck & Co., Inc. had its price target lowered by Royal Bank Of Canada from $150.00 to $145.00. They now have a “sector perform” rating on the stock.
- 10/8/2026 – Merck & Co., Inc. had its price target raised by Cantor Fitzgerald from $120.00 to $145.00. They now have a “neutral” rating on the stock.
- 10/7/2026 – Merck & Co., Inc. had its price target lowered by Morgan Stanley from $179.00 to $177.00. They now have an “overweight” rating on the stock.
- 10/5/2026 – Merck & Co., Inc. had its price target raised by JPMorgan Chase & Co. from $150.00 to $165.00. They now have an “overweight” rating on the stock.
- 10/3/2026 – Merck & Co., Inc. was downgraded by Wall Street Zen from “buy” to “hold”.
- 9/29/2026 – Merck & Co., Inc. had its price target raised by Scotiabank from $155.00 to $180.00. They now have a “sector outperform” rating on the stock.
- 9/23/2026 – Merck & Co., Inc. had its price target raised by TD Cowen from $137.00 to $155.00. They now have a “hold” rating on the stock.
- 9/20/2026 – Merck & Co., Inc. was upgraded by Wall Street Zen from “hold” to “buy”.
Merck & Co., Inc. Trading Down 0.0%
Shares of NYSE MRK opened at $147.74 on Monday. Merck & Co., Inc. has a twelve month low of $91.49 and a twelve month high of $156.92. The firm has a market cap of $364.21 billion, a PE ratio of 152.31, a price-to-earnings-growth ratio of 6.77 and a beta of 0.13. The business has a fifty day simple moving average of $146.16 and a two-hundred day simple moving average of $128.61. The company has a quick ratio of 1.14, a current ratio of 1.35 and a debt-to-equity ratio of 1.11.
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The company reported $2.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.09 by $0.40. The business had revenue of $18.09 billion for the quarter, compared to the consensus estimate of $17.33 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 3.64%. The business’s revenue was up 4.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.58 EPS. Analysts expect that Merck & Co., Inc. will post 2.82 earnings per share for the current fiscal year.
Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company’s research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.
Read More
- Five stocks we like better than Merck & Co., Inc.
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
Receive News & Ratings for Merck & Co Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co Inc and related companies with MarketBeat.com's FREE daily email newsletter.
